• Explore /
  • Poster
  • / Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

Abstract Video & Slides Poster

Authors

Andrea Apolo

Andrea B. Apolo

National Cancer Institute, National Institutes of Health, Bethesda, MD

Andrea B. Apolo , Thomas Powles , Mauricio Burotto , Maria Teresa Bourlon , James J Hsieh , Umberto Basso , Amishi Yogesh Shah , Cristina Suarez , Camillo Porta , Carlos H. Barrios , Howard Gurney , Elizabeth R Kessler , Margitta Retz , Saby George , Bernard Escudier , Joshua Zhang , Burcin Simsek , Christian Scheffold , Robert J. Motzer , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03141177

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4553)

DOI

10.1200/JCO.2021.39.15_suppl.4553

Abstract #

4553

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Amishi Yogesh Shah

First Author: Viktor Grünwald

First Author: David Cella

First Author: Jens Bedke